Teva's first DTC campaign for tardive dyskinesia (TD) drug Austedo launches into a suddenly competitive TV ad space for the rare condition. It joins Neurocrine Biosciences' Ingrezza campaign that ...
PARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the ...
Please provide your email address to receive an email when new articles are posted on . Teva Pharmaceuticals announced FDA approval of Austedo XR, a once-daily, extended-release formulation for adults ...
Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO® (deutetrabenazine) tablets The U.S. Food and Drug Administration ...
Teva Pharmaceuticals recently announced that the FDA approved Austedo tablets for the treatment of tardive dyskinesia in adults. “We are pleased to bring forward this second indication for Austedo to ...
In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback